E2Nomac is developed by Sydney Centre for Reproductive Health Research.

What development phase is E2Nomac in?

E2Nomac is FDA-approved (marketed).

Last reviewed 2026-04-22 · How we verify

E2Nomac

Sydney Centre for Reproductive Health Research · FDA-approved active Small molecule

E2Nomac is a selective estrogen receptor modulator (SERM) that modulates estrogen signaling for reproductive health applications.

E2Nomac is a selective estrogen receptor modulator (SERM) that modulates estrogen signaling for reproductive health applications. Used for Reproductive health applications (specific indication not publicly detailed).

At a glance

Generic name	E2Nomac
Also known as	Zoely
Sponsor	Sydney Centre for Reproductive Health Research
Drug class	Selective Estrogen Receptor Modulator (SERM)
Target	Estrogen receptor (ER-α/ER-β)
Modality	Small molecule
Therapeutic area	Reproductive Health / Gynecology
Phase	FDA-approved

Mechanism of action

E2Nomac acts as a selective estrogen receptor modulator, binding to estrogen receptors with tissue-selective activity. This allows it to provide estrogen agonist effects in some tissues while acting as an antagonist in others, making it suitable for reproductive health indications where selective estrogen modulation is therapeutically beneficial.

Approved indications

Reproductive health applications (specific indication not publicly detailed)

Common side effects

No common side effects on file.

Key clinical trials

A New Treatment Option for Heavy Menstrual Bleeding (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results